Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 42

Trial Status

Completed1
Recruiting1
Other2

Role Distribution

Principal Investigator2
Other Roles2
PI Rate50%

Activity Timeline

Clinical Trials (4)

NCT05355350Phase 4Withdrawn
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections
PrincipalinvestigatorStart date: 2022-07-01
NCT03671967Phase 4Recruiting
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections
StudydirectorStart date: 2019-05-01
NCT03011515Completed
Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
Acute BronchitisChronic Obstructive Pulmonary Disease (COPD)Lower Respiratory Tract Infection+2 more
PrincipalinvestigatorStart date: 2017-03-10
NCT04438837Not ApplicableUnknown
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers
Coronavirus Disease 2019 (COVID-19)Post-Exposure Prophylaxis
Studychair

Research Network

Collaboration Network

7 collaborators·17 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Roni Bitterman, MD

Rambam Health Care Campus

Moderately Similar
2 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)Hadassah Medical Organization+9 more
Collaborated on 2 trials
Similarity Score38%

Noa Eliakim-Raz, MD

Rabin Medical Center, Beilinson Campus

Moderately Similar
2 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)Hadassah Medical Organization+9 more
Collaborated on 2 trials
Similarity Score38%

Cristina Mussini, MD

University of Modena and Reggio Emilia

Moderately Similar
1 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)Hadassah Medical Organization+9 more
Collaborated on 1 trial
Similarity Score34%

Alaa Atamna, MD

Rabin Medical Center, Beilinson Campus

Moderately Similar
1 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Hadassah Medical OrganizationRabin Medical Center+2 more
Collaborated on 1 trial
Similarity Score34%

Leonard Leibovici, MD

Rabin Medical Center

Moderately Similar
1 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)Hadassah Medical Organization+9 more
Collaborated on 1 trial
Similarity Score34%

Dafna Yahav, MD

Sheba Tel HaShomer Medical Campus

Moderately Similar
1 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Hadassah Medical OrganizationRabin Medical Center+2 more
Collaborated on 1 trial
Similarity Score34%

Marie Carmen Valenza, phD

Universidad de Granada

Related
25 trials

Shared therapeutic areas:

Pulmonary Disease, Chronic ObstructivePneumonia
Similarity Score6%

Sidra Afzal, PP-DPT

Riphah International University

Related
19 trials

Shared therapeutic areas:

Pulmonary Disease, Chronic ObstructivePneumonia
Similarity Score6%

Konrad E Bloch, MD

University Hospital, Zürich

Related
19 trials

Shared therapeutic areas:

Pulmonary Disease, Chronic Obstructive
Similarity Score3%

Seetha Shankaran, MD

Wayne State University

Related
49 trials

Shared therapeutic areas:

Pneumonia

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)McGill University Health Centre/Research Institute of the McGill University Health Centre
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT05355350Phase 4PrincipalInvestigator

PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections
Withdrawn
NCT03671967Phase 4StudyDirector

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections
Recruiting
NCT03011515PrincipalInvestigator

Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)

Acute BronchitisChronic Obstructive Pulmonary Disease (COPD)Lower Respiratory Tract Infection+2 more
Completed
NCT04438837Not ApplicableStudyChair

Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers

Coronavirus Disease 2019 (COVID-19)Post-Exposure Prophylaxis
Unknown

All 4 trials loaded